The Genomic Atlas of Breast Cancer — the non-coding theme

Update News

  • GABC update 2020.06.15
  • GABC update 2019.03.20
  • GABC online 2018.08.09
  • Data collection 2018.04.09

About Us

  • Steven Xi Chen:
    steven.chen@miami.edu
  • Yunpeng Zhang:
    YXZ1418@med.miami.edu
  • Peng Wang:
    wpgqy@163.com
  • Shangwei Ning:
    ningsw@ems.hrbmu.edu.cn
  • Xia Li:
    lixia@hrbmu.edu.cn

Detail


Chr chr14
start 100779410
end 100861031
lncRNA name MEG3
entrez id 55384
hgnc id HGNC:14575
ensg id ENSG00000214548
refseq id NR_002766
methods qPCR, Western blot etc.
regulated down-regulated
function description MEG3 was significantly down-regulated in breast cancer tissues compared to adjacent normal tissues.MEG3/miR-421/E-cadherin regulatory axis may be a novel therapeutic target for breast cancer.endogenous miR-421 expression was negatively regulated by MEG3 in breast cancer cells and MEG3 regulated E-cadherin expression by sponging to miR-421 in breast cancer cells.Survival analysis showed that lower MEG3 predicted a poor DFS and OS for patients. Down-regulation of MEG3 enhances cisplatin resistance of lung cancer cells through activation of the WNT/b-catenin signaling pathway.
pubmed id 28463794
year 2017
title LncRNA MEG3 inhibits cell epithelial-mesenchymal transition by sponging miR-421 targeting E-cadherin in breast cancer.
drug V
circulating X
survival V

CopyRight © University of Miami, USA; Harbin Medical University, China